SCHEMBL148480

SCHEMBL148480

NCCCCN[C@@H](CCCCN)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.54
GGT1 P19440 2/20 0.53
GSR P00390 1/20 0.50
RNPEP Q9H4A4 1/20 0.48
TLR2 O60603 1/20 0.45
NOD1 Q9Y239 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
CPB2 Q96IY4 3/20 0.44
SIRT6 Q8N6T7 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
SLC6A5 Q9Y345 1/20 0.42
GNAI3 P08754 1/20 0.40
GNAO1 P09471 1/20 0.40
GNAI1 P63096 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
PAOX Q6QHF9 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7076576 1.00 FOLH1 (0.54) FOLH1GGT1GSRRNPEPTLR2
SCHEMBL31040404 0.98 FOLH1 (0.53) FOLH1GGT1GSRRNPEPTLR2
SCHEMBL28397660 0.98 FOLH1 (0.53) FOLH1GGT1GSRRNPEPTLR2
Hydrochloric Acid SCHEMBL25352316 0.96 FOLH1 (0.51) FOLH1GGT1GSRRNPEPTLR2
SCHEMBL6316197 0.96 FOLH1 (0.54) FOLH1GGT1GSRRNPEPTLR2
SCHEMBL6859366 0.96 FOLH1 (0.54) FOLH1GGT1GSRRNPEPTLR2
SCHEMBL31040389 0.94 GGT1 (0.51) FOLH1GGT1GSRRNPEPTLR2
SCHEMBL29291290 0.93 FOLH1 (0.49) FOLH1GGT1GSRRNPEPTLR2
Hydrochloric Acid SCHEMBL25353775 0.92 GGT1 (0.50) FOLH1GGT1GSRRNPEPTLR2
Hydrochloric Acid SCHEMBL25353778 0.92 GGT1 (0.50) FOLH1GGT1GSRRNPEPTLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US claimed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO claimed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP claimed
CN-117098544-A Diterpenoid compounds acting on Protein Kinase C (PKC) K-GEN治疗股份有限公司 2023-11-21 CN claimed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US claimed
WO-2022204327-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN, INC. (US) 2022-09-29 WO claimed
EP-4041268-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen, Inc. (US) 2022-08-17 EP claimed
CN-114786697-A Diterpenoids acting on Protein Kinase C (PKC) K-GEN股份有限公司 2022-07-22 CN claimed
EP-2413711-A1 DIPEPTIDE AS FEEDSTUFF ADDITIVE Evonik Degussa GmbH (DE) 2012-02-08 EP claimed
WO-2010112365-A1 DIPEPTIDE AS FEEDSTUFF ADDITIVE EVONIK DEGUSSA GMBH (DE) 2010-10-07 WO claimed
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES VICTORIA LINK LIMITED (NZ) 2024-08-29 US disclosed
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
EP-4351581-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES Victoria Link Limited (NZ) 2024-04-17 EP disclosed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO disclosed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP disclosed
EP-1200468-A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF i STAPHYLOCOCCUS AUREUS /i ELONGATION FACTOR P PHARMACIA & UPJOHN COMPANY (US) 2002-05-02 EP disclosed
WO-2001010906-A9 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS ELONGATION FACTOR P UPJOHN CO (US) 2002-04-11 WO disclosed
WO-2001010906-A1 CRYSTALLIZATION AND STRUCTURE DETERMINATION OF STAPHYLOCOCCUS AUREUS ELONGATION FACTOR P PHARMACIA & UPJOHN COMPANY (US) 2001-02-15 WO disclosed
WO-1994015596-A1 COMPOSITIONS AND METHODS FOR INHIBITING DEOXYHYPUSINE SYNTHASE AND THE GROWTH OF CELLS THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-07-21 WO disclosed
WO-1992005190-A1 DEOXYHYPUSYL HYDROXYLASE INHIBITORS THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 1992-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES EBNA1BP2, RPL35, RPL7 FOLH1 2475/4885GGT1 811/4885GSR 2412/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB FOLH1 2409/4885GGT1 652/4885GSR 1348/4885
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCB, PRKCI FOLH1 4247/4885GGT1 887/4885GSR 2564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.